Department of Genetics and Cell Biology, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin 300071, China.
J Pathol. 2012 Mar;226(4):666-73. doi: 10.1002/path.3026. Epub 2012 Jan 17.
CLIP-170 is a microtubule-binding protein and participates in diverse microtubule-associated cellular activities by regulating microtubule dynamics. Here we provide evidence that CLIP-170 is a mediator of the sensitivity of the anti-microtubule drug paclitaxel in breast cancer. In vitro cell proliferation assays reveal that CLIP-170 expression in breast cancer cell lines correlates with their sensitivity to paclitaxel. In addition, CLIP-170 expression in clinical samples of breast cancer correlates with the pathological response of tumours to paclitaxel-containing chemotherapy. Mitotic index and caspase-3 activity analyses reveal that CLIP-170 increases the abilities of paclitaxel to block cell cycle progression at mitosis and to induce apoptosis in breast cancer cells. By microtubule sedimentation assay and binding affinity analysis, we further find that CLIP-170 promotes paclitaxel binding to microtubules. In vitro tubulin polymerization assay shows that CLIP-170 enhances the activity of paclitaxel to promote microtubule assembly. These results demonstrate that CLIP-170 mediates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
CLIP-170 是一种微管结合蛋白,通过调节微管动力学参与多种与微管相关的细胞活动。在这里,我们提供证据表明 CLIP-170 是乳腺癌中抗微管药物紫杉醇敏感性的介质。体外细胞增殖实验表明,乳腺癌细胞系中 CLIP-170 的表达与其对紫杉醇的敏感性相关。此外,乳腺癌临床样本中的 CLIP-170 表达与肿瘤对含紫杉醇化疗的病理反应相关。有丝分裂指数和 caspase-3 活性分析表明,CLIP-170 增加了紫杉醇在有丝分裂时阻止细胞周期进程和诱导乳腺癌细胞凋亡的能力。通过微管沉淀实验和结合亲和力分析,我们进一步发现 CLIP-170 促进紫杉醇与微管的结合。体外微管聚合实验表明,CLIP-170 增强了紫杉醇促进微管组装的活性。这些结果表明,CLIP-170 通过微管依赖性机制介导乳腺癌中紫杉醇的敏感性。